文献速递心脑血管急症

灌注影像指导卒中发病9小时内溶栓

Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
PubMed 文献 · N Engl J Med · 2019-01-01
一句话结论灌注影像筛选的缺血性卒中患者发病4.5-9.0小时或醒后卒中时使用阿替普酶,90天无或轻微神经功能缺损比例高于安慰剂,但症状性颅内出血更多。

这项多中心随机安慰剂对照试验纳入自动灌注影像显示低灌注但有可挽救脑组织的缺血性卒中患者,随机在发病4.5-9.0小时或醒后卒中(睡眠中点后9小时内)接受静脉阿替普酶或安慰剂。主要终点90天改良Rankin量表0或1分在阿替普酶组40例(35.4%)、安慰剂组33例(29.5%),校正风险比1.44(95%CI 1.01-2.06,P=0.04)。症状性颅内出血阿替普酶组7例(6.2%)、安慰剂组1例(0.9%),校正风险比7.22(95%CI 0.97-53.5,P=0.05)。改良Rankin量表评分分布的次要序贯分析未显示90天功能改善的显著组间差异。

要点

  • 自动灌注影像筛选低灌注但可挽救脑组织的缺血性卒中患者,发病4.5-9.0小时或醒后卒中(睡眠中点后9小时内)可考虑静脉阿替普酶。
  • 90天改良Rankin量表0或1分:阿替普酶组40/113例(35.4%)vs 安慰剂组33/112例(29.5%),校正风险比1.44(95%CI 1.01-2.06,P=0.04)。
  • 症状性颅内出血:阿替普酶组7/113例(6.2%)vs 安慰剂组1/112例(0.9%),校正风险比7.22(95%CI 0.97-53.5,P=0.05)。
  • 改良Rankin量表评分分布的次要序贯分析未显示90天功能改善的显著组间差异。
  • 试验在计划310例中入组225例后因另一试验阳性结果发表致均衡丧失而提前终止,实际随机阿替普酶组113例、安慰剂组112例。

适用人群与场景

  • 缺血性卒中患者,自动灌注影像显示低灌注但有可挽救脑组织。
  • 发病4.5-9.0小时或醒后卒中(睡眠中点后9小时内)。

处置流程与药物剂量

  • 静脉阿替普酶或安慰剂,在发病4.5-9.0小时或醒后卒中(睡眠中点后9小时内)给药;原文未写明具体剂量、途径频次和疗程。

红旗征与不能漏的情况

  • 症状性颅内出血:阿替普酶组7例(6.2%)vs 安慰剂组1例(0.9%),校正风险比7.22(95%CI 0.97-53.5,P=0.05)。

研究设计与关键结果

  • 多中心、随机、安慰剂对照试验,实际随机阿替普酶组113例、安慰剂组112例,计划310例中入组225例后提前终止。
  • 主要终点90天改良Rankin量表0或1分:阿替普酶组40例(35.4%)vs 安慰剂组33例(29.5%),校正年龄和基线临床严重程度的风险比1.44(95%CI 1.01-2.06,P=0.04)。
  • 症状性颅内出血:阿替普酶组7例(6.2%)vs 安慰剂组1例(0.9%),校正风险比7.22(95%CI 0.97-53.5,P=0.05)。
  • 改良Rankin量表评分分布的次要序贯分析未显示90天功能改善的显著组间差异。

证据类型、等级与局限

  • 随机、安慰剂对照试验;原文未报告证据等级。
  • 局限:试验在计划310例中入组225例后因另一试验阳性结果发表致均衡丧失而提前终止;实际样本量阿替普酶组113例、安慰剂组112例;症状性颅内出血风险比95%CI宽(0.97-53.5)。

对床旁实践的改变

  • 对自动灌注影像显示低灌注但有可挽救脑组织的缺血性卒中患者,发病4.5-9.0小时或醒后卒中(睡眠中点后9小时内),阿替普酶较安慰剂提高90天无或轻微神经功能缺损比例(35.4% vs 29.5%)。
  • 阿替普酶组症状性颅内出血多于安慰剂组(6.2% vs 0.9%),风险比95%CI宽且未达统计学显著。
  • 改良Rankin量表评分分布的次要序贯分析未显示90天功能改善的显著组间差异。

指南或共识出处

  • EXTEND trial; ClinicalTrials.gov numbers, NCT00887328 and NCT01580839.

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging.

METHODS: We conducted a multicenter, randomized, placebo-controlled trial involving patients with ischemic stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion imaging. The patients were randomly assigned to receive intravenous alteplase or placebo between 4.5 and 9.0 hours after the onset of stroke or on awakening with stroke (if within 9 hours from the midpoint of sleep). The primary outcome was a score of 0 or 1 on the modified Rankin scale, on which scores range from 0 (no symptoms) to 6 (death), at 90 days. The risk ratio for the primary outcome was adjusted for age and clinical severity at baseline.

RESULTS: After 225 of the planned 310 patients had been enrolled, the trial was terminated because of a loss of equipoise after the publication of positive results from a previous trial. A total of 113 patients were randomly assigned to the alteplase group and 112 to the placebo group. The primary outcome occurred in 40 patients (35.4%) in the alteplase group and in 33 patients (29.5%) in the placebo group (adjusted risk ratio, 1.44; 95% confidence interval [CI], 1.01 to 2.06; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 7 patients (6.2%) in the alteplase group and in 1 patient (0.9%) in the placebo group (adjusted risk ratio, 7.22; 95% CI, 0.97 to 53.5; P = 0.05). A secondary ordinal analysis of the distribution of scores on the modified Rankin scale did not show a significant between-group difference in functional improvement at 90 days.

CONCLUSIONS: Among the patients in this trial who had ischemic stroke and salvageable brain tissue, the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo. There were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group. (Funded by the Australian National Health and Medical Research Council and others; EXTEND ClinicalTrials.gov numbers, NCT00887328 and NCT01580839.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019. PMID: 31067369. doi:10.1056/NEJMoa1813046

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。